Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Role of TPMT and ITPA variants in mercaptopurine disposition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Felipe K Hurtado
  • Filippo de Braud
  • Javier De Castro Carpeño
  • Maria Jose de Miguel Luken
  • Ding Wang
  • Jeffrey Scott
  • Yvonne Y Lau
  • Tracey McCulloch
  • Morten Mau-Sorensen
Vis graf over relationer

PURPOSE: Ceritinib is an ALK receptor tyrosine kinase inhibitor approved as first- and second-line treatment in adult patients with ALK + metastatic non-small cell lung cancer (NSCLC). The study investigated the drug-drug interaction (DDI) potential of ceritinib when coadministered with midazolam and warfarin as probe substrates for CYP3A and CYP2C9 activity, respectively.

METHODS: This was a phase I, multicenter, open-label, single sequence, crossover DDI study in 33 adult patients with ALK + NSCLC or other advanced tumors. A single dose of a cocktail consisting of midazolam and warfarin was administered with and without concomitant administration of ceritinib. The primary objective was to evaluate the pharmacokinetics of midazolam and warfarin. Secondary objectives included pharmacokinetics, safety, tolerability, overall response rate (ORR), and duration of response (DOR) of ceritinib 750 mg once daily.

RESULTS: Ceritinib inhibited CYP3A-mediated metabolism of midazolam, resulting in a markedly increased AUC (geometric mean ratio [90% confidence interval]) by 5.4-fold (4.6, 6.3). Ceritinib also led to an increase in the AUC of S-warfarin by 54% (36%, 75%). The pharmacokinetics and safety profile of ceritinib in this study are consistent with previous reports and no new safety signals were reported. Among the 19 patients with NSCLC, efficacy (ORR: 42.1% and DCR: 63.2%) was similar to that reported previously in studies of pretreated patients with ALK + NSCLC.

CONCLUSION: Ceritinib is a strong CYP3A inhibitor and a weak CYP2C9 inhibitor. These findings should be reflected as actionable clinical recommendations in the prescribing information for ceritinib with regards to concomitant medications whose pharmacokinetics may be altered by ceritinib.

TidsskriftCancer Chemotherapy and Pharmacology
Udgave nummer4
Sider (fra-til)475-486
Antal sider12
StatusUdgivet - apr. 2021

ID: 64232048